SCHEMBL2919987

SCHEMBL2919987

Cc1cccc2cnc(Nc3ccc4c(c3)CCC4)nc12

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
STK17A Q9UEE5 3/20 0.54
STK17B O94768 2/20 0.48
CDK5 Q00535 4/20 0.48
CDK5R1 Q15078 4/20 0.48
CCNA2 P20248 3/20 0.48
CDK2 P24941 3/20 0.48
CDK1 P06493 1/20 0.48
CCNB1 P14635 1/20 0.48
RAPGEF4 Q8WZA2 1/20 0.47
EGFR P00533 1/20 0.46
SYK P43405 1/20 0.46
BTK Q06187 5/20 0.45
JUN P05412 1/20 0.43
MAPK10 P53779 1/20 0.43
GRM5 P41594 2/20 0.43
MAOB P27338 1/20 0.43
IGF1R P08069 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2919611 0.81 L3MBTL1 (0.51) STK17ASTK17BCDK2CDK1CCNB1
SCHEMBL2924377 0.81 PIM1 (0.45) STK17ACDK5CDK5R1CCNA2CDK2
SCHEMBL2916705 0.78 KDR (0.52) CDK2CDK1CCNB1EGFRSYK
SCHEMBL10187807 0.77 STK17A (0.61) STK17ASTK17BCDK5CDK5R1EGFR
SCHEMBL2910655 0.77 JUN (0.61) STK17ASTK17BEGFRSYKJUN
SCHEMBL2917914 0.77 SYK (0.56) CDK1EGFRSYKBTKJUN
SCHEMBL2918539 0.77 JUN (0.70) STK17ASTK17BCDK2CDK1JUN
SCHEMBL2913599 0.76 KDR (0.56) CDK2CDK1CCNB1RAPGEF4EGFR
SCHEMBL12999377 0.76 ABL1 (0.58) CDK5CDK2RAPGEF4EGFRSYK
SCHEMBL2912369 0.76 SYK (0.56) CDK2SYKGRM5MAOBIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K STK17A 295/4885STK17B 374/4885CDK5 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.